Is Compass Therapeutics Stock a Good Investment?
Compass Therapeutics Investment Advice | CMPX |
- Examine Compass Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Compass Therapeutics' leadership team and their track record. Good management can help Compass Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Compass Therapeutics' business and its evolving consumer preferences.
- Compare Compass Therapeutics' performance and market position to its competitors. Analyze how Compass Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Compass Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Compass Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Compass Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Compass Therapeutics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Compass Therapeutics Stock
Researching Compass Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 18.0% of the company shares are held by company insiders. The book value of Compass Therapeutics was currently reported as 0.91. The company recorded a loss per share of 0.36. Compass Therapeutics had not issued any dividends in recent years.
To determine if Compass Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Compass Therapeutics' research are outlined below:
| Compass Therapeutics is way too risky over 90 days horizon | |
| Compass Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 850 K. Net Loss for the year was (49.38 M) with profit before overhead, payroll, taxes, and interest of 850 K. | |
| Compass Therapeutics currently holds about 132.02 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. | |
| Compass Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: 10 Hot Biotech Stocks Under 5 - Insider Monkey |
Compass Therapeutics Quarterly Cash And Short Term Investments |
|
Compass Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Compass Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Compass Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Compass Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Compass Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-03 | 2023-06-30 | -0.08 | -0.09 | -0.01 | 12 | ||
2025-02-27 | 2024-12-31 | -0.0944 | -0.11 | -0.0156 | 16 | ||
2024-03-21 | 2023-12-31 | -0.09 | -0.11 | -0.02 | 22 | ||
2021-11-12 | 2021-09-30 | -0.12 | -0.1 | 0.02 | 16 | ||
2024-11-12 | 2024-09-30 | -0.11 | -0.08 | 0.03 | 27 | ||
2024-05-13 | 2024-03-31 | -0.11 | -0.08 | 0.03 | 27 | ||
2023-11-09 | 2023-09-30 | -0.11 | -0.08 | 0.03 | 27 | ||
2022-05-09 | 2022-03-31 | -0.11 | -0.07 | 0.04 | 36 |
Compass Therapeutics Target Price Consensus
Compass target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Compass Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Compass analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Compass stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Compass Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCompass Therapeutics Target Price Projection
Compass Therapeutics' current and average target prices are 2.24 and 11.00, respectively. The current price of Compass Therapeutics is the price at which Compass Therapeutics is currently trading. On the other hand, Compass Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Compass Therapeutics Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Compass Therapeutics Target Price
Compass Therapeutics Analyst Ratings
Compass Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Compass Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Compass Therapeutics' financials, market performance, and future outlook by experienced professionals. Compass Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Compass Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Compass Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Compass Therapeutics backward and forwards among themselves. Compass Therapeutics' institutional investor refers to the entity that pools money to purchase Compass Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blue Owl Capital Holdings Lp | 2024-12-31 | 3 M | Geode Capital Management, Llc | 2024-12-31 | 2.3 M | State Street Corp | 2024-12-31 | 1.9 M | Baker Bros Advisors Lp | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 801.2 K | Monashee Investment Management Llc | 2024-12-31 | 448.2 K | Sg Americas Securities, Llc | 2024-12-31 | 395 K | Goldman Sachs Group Inc | 2024-12-31 | 390.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 378.6 K | Orbimed Advisors, Llc | 2024-12-31 | 22.4 M | Blackstone Inc | 2024-12-31 | 10 M |
Compass Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 327.73 M.Market Cap |
|
Compass Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.30) | (0.32) | |
| Return On Assets | (0.24) | (0.26) | |
| Return On Equity | (0.33) | (0.35) |
Determining Compass Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Compass Therapeutics is a good buy. For example, gross profit margin measures Compass Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Compass Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Compass Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Compass Therapeutics. Check Compass Therapeutics' Beneish M Score to see the likelihood of Compass Therapeutics' management manipulating its earnings.
Evaluate Compass Therapeutics' management efficiency
Compass Therapeutics has return on total asset (ROA) of (0.2381) % which means that it has lost $0.2381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3607) %, meaning that it created substantial loss on money invested by shareholders. Compass Therapeutics' management efficiency ratios could be used to measure how well Compass Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.26 in 2025. Return On Capital Employed is likely to drop to -0.32 in 2025. Net Tangible Assets is likely to rise to about 219.3 M in 2025, whereas Total Assets are likely to drop slightly above 125.3 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.05 | 1.11 | |
| Tangible Book Value Per Share | 1.05 | 1.11 | |
| Enterprise Value Over EBITDA | (3.26) | (3.42) | |
| Price Book Value Ratio | 1.20 | 1.26 | |
| Enterprise Value Multiple | (3.26) | (3.42) | |
| Price Fair Value | 1.20 | 1.26 | |
| Enterprise Value | 389.3 M | 333.1 M |
Effective leadership at Compass Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 0.999 |
Basic technical analysis of Compass Stock
As of the 25th of March, Compass Therapeutics shows the Mean Deviation of 5.35, risk adjusted performance of 0.124, and Downside Deviation of 5.52. Compass Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Compass Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Compass Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Compass Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Compass Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Compass Therapeutics' Outstanding Corporate Bonds
Compass Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Compass Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Compass bonds can be classified according to their maturity, which is the date when Compass Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US20453KAA34 Corp BondUS20453KAA34 | View | |
| US20451RAC60 Corp BondUS20451RAC60 | View | |
| US20451RAB87 Corp BondUS20451RAB87 | View | |
| Compass Minerals International Corp BondUS20451NAG60 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Compass Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Compass Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.124 | |||
| Market Risk Adjusted Performance | 0.3316 | |||
| Mean Deviation | 5.35 | |||
| Semi Deviation | 5.04 | |||
| Downside Deviation | 5.52 | |||
| Coefficient Of Variation | 783.78 | |||
| Standard Deviation | 7.65 | |||
| Variance | 58.48 | |||
| Information Ratio | 0.1311 | |||
| Jensen Alpha | 1.08 | |||
| Total Risk Alpha | 1.27 | |||
| Sortino Ratio | 0.1816 | |||
| Treynor Ratio | 0.3216 | |||
| Maximum Drawdown | 44.59 | |||
| Value At Risk | (8.88) | |||
| Potential Upside | 14.18 | |||
| Downside Variance | 30.46 | |||
| Semi Variance | 25.36 | |||
| Expected Short fall | (6.83) | |||
| Skewness | 1.36 | |||
| Kurtosis | 3.36 |
| Risk Adjusted Performance | 0.124 | |||
| Market Risk Adjusted Performance | 0.3316 | |||
| Mean Deviation | 5.35 | |||
| Semi Deviation | 5.04 | |||
| Downside Deviation | 5.52 | |||
| Coefficient Of Variation | 783.78 | |||
| Standard Deviation | 7.65 | |||
| Variance | 58.48 | |||
| Information Ratio | 0.1311 | |||
| Jensen Alpha | 1.08 | |||
| Total Risk Alpha | 1.27 | |||
| Sortino Ratio | 0.1816 | |||
| Treynor Ratio | 0.3216 | |||
| Maximum Drawdown | 44.59 | |||
| Value At Risk | (8.88) | |||
| Potential Upside | 14.18 | |||
| Downside Variance | 30.46 | |||
| Semi Variance | 25.36 | |||
| Expected Short fall | (6.83) | |||
| Skewness | 1.36 | |||
| Kurtosis | 3.36 |
Consider Compass Therapeutics' intraday indicators
Compass Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Compass Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 2.24 | |||
| Day Typical Price | 2.24 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.13) | |||
| Relative Strength Index | 42.51 |
Compass Therapeutics Corporate Filings
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 13th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify |
Compass Stock media impact
Far too much social signal, news, headlines, and media speculation about Compass Therapeutics that are available to investors today. That information is available publicly through Compass media outlets and privately through word of mouth or via Compass internal channels. However, regardless of the origin, that massive amount of Compass data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Compass Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Compass Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Compass Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Compass Therapeutics alpha.
Compass Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Compass Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Compass Therapeutics Corporate Management
| Susan Kalled | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Barry JD | Chief Officer | Profile | |
| Neil CPA | Vice Finance | Profile | |
| Peter Moesta | Interim CMC | Profile | |
| Anna Gifford | Communications Manager | Profile |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.